research use only

Tamnorzatinib (ONO-7475) Axl inhibitor

Cat.No.S8933

Tamnorzatinib (ONO-7475) is a potent, selective, and orally active novel inhibitor of Anexelekto(Axl)/MER tyrosine kinase with IC50 of 0.7 nM and 1.0 nM for AXL and MER, respectively. This compound suppresses the emergence and maintenance of tolerant cells to the initial EGFR-TKIs, osimertinib or dacomitinib, in AXL-overexpressing EGFR-mutated NSCLC cells. It also arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells.
Tamnorzatinib (ONO-7475) Axl inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 562.57

Quality Control

Batch: S893301 DMSO]100 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.38%
99.38

Chemical Information, Storage & Stability

Molecular Weight 562.57 Formula

C32H26N4O6

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1646839-59-9 -- Storage of Stock Solutions

Synonyms N/A Smiles COC1=CC2=C(C=CN=C2C=C1OC)OC3=CN=C(C=C3)NC(=O)C4=CC5=C(CCCC5=O)N(C4=O)C6=CC=CC=C6

Solubility

In vitro
Batch:

DMSO : 100 mg/mL ( (177.75 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
Axl [1]
(Cell-free assay)
0.7 nM
Mer [1]
(Cell-free assay)
1.0 nM
FLT3 [1]
(Cell-free assay)
147 nM
In vitro

Tamnorzatinib (ONO-7475) is an inhibitor with high specificity for Anexelekto and MER Tyrosine Kinase. It kills or growth arrests FLT3-ITD AML cells. AraC as well as p53 reduction augments ONO-7475-induced apoptosis in MOLM13 cells. Inhibition of AXL suppresses survival and proliferation signaling and induces apoptotic proteins in FLT3-ITD but not WT FLT3 AML cells.[1] This compound sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs osimertinib and dacomitinib. In addition, it suppresses the emergence and maintenance of EGFR-TKI tolerant cells.[2]

In vivo

Tamnorzatinib (ONO-7475) is effective in a murine in vivo xenograft model using MOLM13 cells. It prolongs mouse survival and suppresses AML cell infiltration in the liver in the AML xenograft model. This compound is efficacious for AML therapy and warrants pursuit for development of the drug in the clinic.[1] In the xenograft models of AXL-overexpressing EGFR mutated lung cancer treated with initial combination therapy of ONO-7475 and osimertinib markedly regresses tumors and delays tumor re-growth.[2]

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03176277 Terminated
Acute Leukemia|Myelodysplastic Syndromes
Ono Pharmaceutical Co. Ltd
June 26 2017 Phase 1|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.